Malignant Pleural Mesothelioma-Pipeline Review, H2 2016

Malignant Pleural Mesothelioma-Pipeline Review, H2 2016


  • Products Id :- GMDHC8690IDB
  • |
  • Pages: 315
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Malignant Pleural Mesothelioma-Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Malignant Pleural Mesothelioma-Pipeline Review, H2 2016, provides an overview of the Malignant Pleural Mesothelioma (Oncology) pipeline landscape.

Malignant pleural mesothelioma is a rare cancer often diagnosed in people who have been exposed to high levels of asbestos. The malignancy affects the pleura, a thin membrane of lubricating cells that lines the lungs and chest wall. Peritoneal mesothelioma originates in the abdomen and as a result, symptoms often include abdominal pain, weight loss, nausea, and vomiting. Other symptoms include anemia, bowel obstructions, chest pain and hemoptysis.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Malignant Pleural Mesothelioma-Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Malignant Pleural Mesothelioma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Malignant Pleural Mesothelioma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Malignant Pleural Mesothelioma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 4, 25, 11 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 2, 4 and 2 molecules, respectively.Malignant Pleural Mesothelioma.

Malignant Pleural Mesothelioma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Malignant Pleural Mesothelioma (Oncology).

The pipeline guide reviews pipeline therapeutics for Malignant Pleural Mesothelioma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Malignant Pleural Mesothelioma (Oncology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Malignant Pleural Mesothelioma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Malignant Pleural Mesothelioma (Oncology)

Reasons To Buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Malignant Pleural Mesothelioma (Oncology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Malignant Pleural Mesothelioma (Oncology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Malignant Pleural Mesothelioma Overview 8

Therapeutics Development 9

Pipeline Products for Malignant Pleural Mesothelioma-Overview 9

Pipeline Products for Malignant Pleural Mesothelioma-Comparative Analysis 10

Malignant Pleural Mesothelioma-Therapeutics under Development by Companies 11

Malignant Pleural Mesothelioma-Therapeutics under Investigation by Universities/Institutes 13

Malignant Pleural Mesothelioma-Pipeline Products Glance 14

Late Stage Products 14

Clinical Stage Products 15

Early Stage Products 16

Malignant Pleural Mesothelioma-Products under Development by Companies 17

Malignant Pleural Mesothelioma-Products under Investigation by Universities/Institutes 20

Malignant Pleural Mesothelioma-Companies Involved in Therapeutics Development 21

Advantagene, Inc. 21

Amphera BV 22

AnGes MG, Inc. 23

ArQule, Inc. 24

Bayer AG 25

Biogen Inc 26

Bionomics Limited 27

Biotecnol Limited 28

Boehringer Ingelheim GmbH 29

Boston Biomedical, Inc. 30

Bristol-Myers Squibb Company 31

CanBas Co., Ltd. 32

Concordia International Corp 33

Eli Lilly and Company 34

EnGeneIC Ltd 35

F. Hoffmann-La Roche Ltd. 36

Genelux Corporation 37

GlaxoSmithKline Plc 38

Juno Therapeutics Inc. 39

MedImmune LLC 40

Merck & Co., Inc. 41

Millennium Pharmaceuticals Inc 42

MolMed S.p.A. 43

Morphotek, Inc. 44

Novartis AG 45

Ono Pharmaceutical Co., Ltd. 46

Oxford BioMedica Plc 47

Pharma Mar, S.A. 48

Polaris Pharmaceuticals, Inc. 49

Sellas Inc 50

Targovax ASA 51

VasGene Therapeutics, Inc. 52

Verastem, Inc. 53

Virttu Biologics Limited 54

Vyriad Inc 55

Malignant Pleural Mesothelioma-Therapeutics Assessment 56

Assessment by Monotherapy Products 56

Assessment by Combination Products 57

Assessment by Target 58

Assessment by Mechanism of Action 61

Assessment by Route of Administration 64

Assessment by Molecule Type 66

Drug Profiles 68

alisertib-Drug Profile 68

amatuximab-Drug Profile 74

anetumab ravtansine-Drug Profile 76

bevacizumab-Drug Profile 79

BG-00001-Drug Profile 88

BMS-986148-Drug Profile 89

BNC-105-Drug Profile 90

CBP-501-Drug Profile 95

Cellular Immunotherapy for Malignant Pleural Mesothelioma and Advanced Leukemia-Drug Profile 97

Cellular Immunotherapy to Target Mesothelin for Oncology-Drug Profile 98

Cellular Immunotherapy to Target WT1 for Oncology-Drug Profile 99

CSG-MESO-Drug Profile 100

defactinib hydrochloride-Drug Profile 101

durvalumab-Drug Profile 108

durvalumab + tremelimumab-Drug Profile 119

galinpepimut-S-Drug Profile 123

ganetespib-Drug Profile 126

GEN-0101-Drug Profile 138

Gene Therapy for Malignant Pleural Mesothelioma-Drug Profile 140

Gene Therapy to Activate NK4 for Malignant Pleural Mesothelioma-Drug Profile 141

GLONC-1-Drug Profile 142

GSK-2256098-Drug Profile 146

HSV-1716-Drug Profile 148

iCasp9M28z-Drug Profile 151

JTCR-016-Drug Profile 152

LY-3023414-Drug Profile 154

MesoCancerVac-Drug Profile 156

MesoCART-Drug Profile 157

Monoclonal Antibody Conjugate to Target Mesothelin for Oncology-Drug Profile 158

MTG-201-Drug Profile 160

napabucasin-Drug Profile 162

NGR-hTNF-Drug Profile 169

nintedanib-Drug Profile 175

nivolumab-Drug Profile 184

Oncolytic Virus for Malignant Pleural Mesothelioma-Drug Profile 218

Oncolytic Virus to Target CD46 for Malignant Pleural Mesothelioma-Drug Profile 219

ONCOS-102-Drug Profile 220

OXB-301-Drug Profile 223

pegargiminase-Drug Profile 226

pembrolizumab-Drug Profile 233

porfimer sodium-Drug Profile 266

rAd-IFN-Drug Profile 268

S-588210-Drug Profile 270

Stem Cell Therapy to Target TRAIL Receptor for Malignant Pleural Mesothelioma and Mestatic Lung Cancer-Drug Profile 271

TargomiRs-Drug Profile 272

TB-535-Drug Profile 274

tivantinib-Drug Profile 275

trabectedin-Drug Profile 280

Vas-01-Drug Profile 287

VS-5584-Drug Profile 289

Malignant Pleural Mesothelioma-Dormant Projects 292

Malignant Pleural Mesothelioma-Discontinued Products 293

Malignant Pleural Mesothelioma-Product Development Milestones 294

Featured News & Press Releases 294

Appendix 310

Methodology 310

Coverage 310

Secondary Research 310

Primary Research 310

Expert Panel Validation 310

Contact Us 310

Disclaimer 311

List of Figures

Number of Products under Development for Malignant Pleural Mesothelioma, H2 2016 13

Number of Products under Development for Malignant Pleural Mesothelioma-Comparative Analysis, H2 2016 14

Number of Products under Development by Companies, H2 2016 15

Number of Products under Investigation by Universities/Institutes, H2 2016 17

Comparative Analysis by Clinical Stage Development, H2 2016 19

Comparative Analysis by Early Stage Products, H2 2016 20

Assessment by Monotherapy Products, H2 2016 60

Number of Products by Top 10 Targets, H2 2016 62

Number of Products by Stage and Top 10 Targets, H2 2016 62

Number of Products by Top 10 Mechanism of Actions, H2 2016 65

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 65

Number of Products by Top 10 Routes of Administration, H2 2016 68

Number of Products by Stage and Top 10 Routes of Administration, H2 2016 68

Number of Products by Top 10 Molecule Types, H2 2016 70

Number of Products by Stage and Top 10 Molecule Types, H2 2016 70

List of Tables

Number of Products under Development for Malignant Pleural Mesothelioma, H2 2016 13

Number of Products under Development for Malignant Pleural Mesothelioma-Comparative Analysis, H2 2016 14

Number of Products under Development by Companies, H2 2016 15

Number of Products under Development by Companies, H2 2016 (Contd..1) 16

Number of Products under Investigation by Universities/Institutes, H2 2016 17

Comparative Analysis by Late Stage Development, H2 2016 18

Comparative Analysis by Clinical Stage Development, H2 2016 19

Comparative Analysis by Early Stage Development, H2 2016 20

Products under Development by Companies, H2 2016 21

Products under Development by Companies, H2 2016 (Contd..1) 22

Products under Development by Companies, H2 2016 (Contd..2) 23

Products under Investigation by Universities/Institutes, H2 2016 24

Malignant Pleural Mesothelioma-Pipeline by Advantagene, Inc., H2 2016 25

Malignant Pleural Mesothelioma-Pipeline by Amphera BV, H2 2016 26

Malignant Pleural Mesothelioma-Pipeline by AnGes MG, Inc., H2 2016 27

Malignant Pleural Mesothelioma-Pipeline by ArQule, Inc., H2 2016 28

Malignant Pleural Mesothelioma-Pipeline by Bayer AG, H2 2016 29

Malignant Pleural Mesothelioma-Pipeline by Biogen Inc, H2 2016 30

Malignant Pleural Mesothelioma-Pipeline by Bionomics Limited, H2 2016 31

Malignant Pleural Mesothelioma-Pipeline by Biotecnol Limited, H2 2016 32

Malignant Pleural Mesothelioma-Pipeline by Boehringer Ingelheim GmbH, H2 2016 33

Malignant Pleural Mesothelioma-Pipeline by Boston Biomedical, Inc., H2 2016 34

Malignant Pleural Mesothelioma-Pipeline by Bristol-Myers Squibb Company, H2 2016 35

Malignant Pleural Mesothelioma-Pipeline by CanBas Co., Ltd., H2 2016 36

Malignant Pleural Mesothelioma-Pipeline by Concordia International Corp, H2 2016 37

Malignant Pleural Mesothelioma-Pipeline by Eli Lilly and Company, H2 2016 38

Malignant Pleural Mesothelioma-Pipeline by EnGeneIC Ltd, H2 2016 39

Malignant Pleural Mesothelioma-Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 40

Malignant Pleural Mesothelioma-Pipeline by Genelux Corporation, H2 2016 41

Malignant Pleural Mesothelioma-Pipeline by GlaxoSmithKline Plc, H2 2016 42

Malignant Pleural Mesothelioma-Pipeline by Juno Therapeutics Inc., H2 2016 43

Malignant Pleural Mesothelioma-Pipeline by MedImmune LLC, H2 2016 44

Malignant Pleural Mesothelioma-Pipeline by Merck & Co., Inc., H2 2016 45

Malignant Pleural Mesothelioma-Pipeline by Millennium Pharmaceuticals Inc, H2 2016 46

Malignant Pleural Mesothelioma-Pipeline by MolMed S.p.A., H2 2016 47

Malignant Pleural Mesothelioma-Pipeline by Morphotek, Inc., H2 2016 48

Malignant Pleural Mesothelioma-Pipeline by Novartis AG, H2 2016 49

Malignant Pleural Mesothelioma-Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016 50

Malignant Pleural Mesothelioma-Pipeline by Oxford BioMedica Plc, H2 2016 51

Malignant Pleural Mesothelioma-Pipeline by Pharma Mar, S.A., H2 2016 52

Malignant Pleural Mesothelioma-Pipeline by Polaris Pharmaceuticals, Inc., H2 2016 53

Malignant Pleural Mesothelioma-Pipeline by Sellas Inc, H2 2016 54

Malignant Pleural Mesothelioma-Pipeline by Targovax ASA, H2 2016 55

Malignant Pleural Mesothelioma-Pipeline by VasGene Therapeutics, Inc., H2 2016 56

Malignant Pleural Mesothelioma-Pipeline by Verastem, Inc., H2 2016 57

Malignant Pleural Mesothelioma-Pipeline by Virttu Biologics Limited, H2 2016 58

Malignant Pleural Mesothelioma-Pipeline by Vyriad Inc, H2 2016 59

Assessment by Monotherapy Products, H2 2016 60

Assessment by Combination Products, H2 2016 61

Number of Products by Stage and Target, H2 2016 63

Number of Products by Stage and Mechanism of Action, H2 2016 66

Number of Products by Stage and Route of Administration, H2 2016 69

Number of Products by Stage and Molecule Type, H2 2016 71

Malignant Pleural Mesothelioma-Dormant Projects, H2 2016 296

Malignant Pleural Mesothelioma-Discontinued Products, H2 2016 297

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Advantagene, Inc., Amphera BV, AnGes MG, Inc., ArQule, Inc., Bayer AG, Biogen Inc, Bionomics Limited, Biotecnol Limited, Boehringer Ingelheim GmbH, Boston Biomedical, Inc., Bristol-Myers Squibb Company, CanBas Co., Ltd., Concordia International Corp, Eli Lilly and Company, EnGeneIC Ltd, F. Hoffmann-La Roche Ltd., Genelux Corporation, GlaxoSmithKline Plc, Juno Therapeutics Inc., MedImmune LLC, Merck & Co., Inc., Millennium Pharmaceuticals Inc, MolMed S.p.A., Morphotek, Inc., Novartis AG, Ono Pharmaceutical Co., Ltd., Oxford BioMedica Plc, Pharma Mar, S.A., Polaris Pharmaceuticals, Inc., Sellas Inc, Targovax ASA, VasGene Therapeutics, Inc., Verastem, Inc., Virttu Biologics Limited, Vyriad Inc

Malignant Pleural Mesothelioma Therapeutic Products under Development, Key Players in Malignant Pleural Mesothelioma Therapeutics, Malignant Pleural Mesothelioma Pipeline Overview, Malignant Pleural Mesothelioma Pipeline, Malignant Pleural Mesothelioma Pipeline Assessment

select a license

Single User License
USD 2000 INR 128720
Site License
USD 4000 INR 257440
Corporate User License
USD 6000 INR 386160

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com